- Published at
- by manilatimes.net
mixed
mixed
News for Seagen Inc. (0A8R.L)
- Published at
- by gurufocus.com
mixedmixedXencor Appoints Todd Simpson to Board of Directors
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, to- Published at
- by gurufocus.com
mixedmixedZai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has accepted the Biologics License Appl- Published at
- by prweb.com
mixedmixedAmbrosia Biosciences Further Strengthens Board of Directors with Appointment of Jason Haddock
/PRNewswire-PRWeb/ -- Ambrosia Biosciences Inc. ("Ambrosia"), today announced the appointment of Jason Haddock to the Board of Directors and as Chair of the...- Published at
- by gurufocus.com
mixedmixedZai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced positive topline results from the China subpopulation of the global Phase 3 innovaTV 301 study, demo- Published at
- by investing.com
mixedmixedZai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer By Investing.com
Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer- Published at
- by gurufocus.com
mixedmixedBelantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse
GSK plc (LSE/NYSE: GSK) today announced statistically significant and clinically meaningful overall survival (OS) results from a planned interim analysis of th- Published at
- by gurufocus.com
neutralneutralHUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (”HUTCHMED” or the ”Company”) (Nasdaq/AIM:HC- Published at
- by manilatimes.net
neutralneutral- Published at
- by investing.com
mixedmixedGenmab Announces Financial Results for the First Nine Months of 2024 By Investing.com
Genmab Announces Financial Results for the First Nine Months of 2024- Published at
- by livemint.com
mixedmixedPfizer CEO, Under Fire, Will Do ‘Whatever It Takes’ to Grow
Pfizer Inc. Chief Executive Officer Albert Bourla said he’ll do “whatever it takes” to keep profits growing, including further cost cuts, as he seeks to fend off allegations of mismanagement from activist investor Starboard Value LP.- Published at
- by gurufocus.com
neutralneutralPfizer (PFE) Reports Strong Q3 Results, Raises 2024 Guidance Amid Investor Pressures
Pfizer (PFE) has released its third-quarter financial results, exceeding market expectations and leading to an upward revision of its full-year 2024 revenue and- Published at
- by finance.yahoo.com
mixedmixedActivist Starboard Value Takes $1 Billion Stake in Pfizer
(Bloomberg) -- Activist investor Starboard Value has taken a stake of about $1 billion in Pfizer Inc. and is seeking to spur a turnaround of the struggling pharmaceuticals giant, according to a person familiar with the matter.Most Read from BloombergSingapore Ends 181 Years of Horse Racing to Make Way for HomesFrom Cleveland to Chicago, NFL Teams Dream of Domed StadiumsWhat Do US Vehicle Regulators Have Against Tiny Cars?For a Master of Brutalist Provocations, a Modest Museum AppraisalMexico Cit- Published at
- by business-standard.com
mixedmixedJapanese firm Daiichi wants to go alone in search of targeted cancer drugs
AstraZeneca Plc and Daiichi's breast cancer drug Enhertu is based off of Daiichi's antibody-drug conjugate platform DXd, and was the top-selling ADC globally in 2023- Published at
- by globenewswire.com
mixedmixedAntibody Drug Conjugates Market Is Expected To Reach Revenue Of USD 51.2 Bn By 2033, at 15.8% CAGR: Dimension Market Research
Advancements and Projections in the Antibody Drug Conjugates Market: Insights, Trends, Opportunities, and Recent Developments...- Published at
- by globenewswire.com
mixedmixedGlobal Stem Cell Market to Cross ~USD 29 Billion Mark by 2030 | DelveInsight
The stem cell market is experiencing positive growth due to several factors, including the increasing prevalence of chronic diseases, the need for drug...- Published at
- by globenewswire.com
mixedmixedGlobal Next-Generation Complement Therapeutics Market to Surge Significantly at a CAGR of ~15% by 2030 | DelveInsight
The next-generation complement therapeutics market is experiencing positive growth driven by the rising global incidence of cardiovascular, genetic,...- Published at
- by globenewswire.com
mixedmixedAdvanced Melanoma Clinical Trial Pipeline Analysis Demonstrates 55+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight
Advanced melanoma is when melanoma cells spread from where they started (the primary melanoma) to other parts of the body. The advanced melanoma...- Published at
- by globenewswire.com
mixedmixedPI3K Inhibitors Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 75+ Companies Working in the Domain
PI3K inhibitors are primarily used in the treatment of various cancers, including breast cancer, lymphoma, and leukemia. With the global burden of cancer...- Published at
- by seekingalpha.com
mixedmixed